Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 236-068-5 | CAS number: 13138-45-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Value used for CSA (read-across from Nickel sulphate):
NOAEL (oral, systemic, animal): 10 mg Ni sulphate hexahydrate /kg bw/day (or 2.2 mg Ni/kg bw/day) (Heim et al. 2007)
NOAEC (inhalation, local, animal): 0.12 mg Ni sulphate hexahydrate /m³ air ( or 0.027 mg Ni/m3air) (Dunnick et al., 1995)
LOAEC(inhalation, local, animal): 0.25 mg nickel sulphate hexahydrate/m3(or 0.056 mg Ni/m3)(Dunnick et al., 1995)
Key value for chemical safety assessment
Additional information
Data for repeated-dose toxicity via oral exposure are read-across from Ni sulphate. In addition, a summary document on the read-across assessment and systemic oral toxicity of nickel compounds can be found as a background document in Appendix B1 of the CSR (and Section 7.5.1 of IUCLID).In a 2- year OECD 451 carcinogenicity study, decreased body weight gain ranging from 4% to 12% was recorded (males and females combined) following oral gavage of 2.2 to 11 mg Ni/kg bw/day. A dose-related reduced survival achieving statistical significance at the two highest dose levels was seen in females (Heim et al., 2007). The LOAEL of 6.7 mg Ni/kg bw/day based on reduced body weight and increased mortality together with a NOAEL of 2.2 mg Ni/kg bw/day are taken forward to the risk characterisation for oral repeated dose toxicity . These data are considered relevant for the risk assessment of nickelnitrate and are taken forward to the Risk Characterisation.
Data for repeated-dose toxicity via inhalation exposure are read-across from Ni sulphate. Available data included 12 day, 13 week, and 2 year studies with both mice and rats. Hazard and risk assessment are based on the 2 year rat study. Chronic lung inflammation including lung fibrosis results from long-term (2 year) exposure via inhalation to a concentration of 0.056 mg Ni/m3 or 0.25 mg nickel sulphate hexahydrate/m3 (NTP, 1996a; Dunnick et al., 1995). Nickel sulphate fulfils the criteria for classification as STOT RE 1; H372 since chronic lung inflammation including lung fibrosis results from long-term exposure via inhalation to a concentration of 0.056 mg Ni/m3. A LOAEC for repeated dose toxicity via inhalation of 0.056 mg Ni/m3 for lung inflammation and fibrosis, and a NOAEC of 0.027 mg Ni/m3 for these effects based on the chronic study of nickel sulphate by NTP (1996a), are used in the risk characterization of nickel dinitrate.
The following information is taken into account for any hazard / risk assessment:
ORAL: Data are read-across from Ni sulphate. A 2-year oral carcinogenicity study reported a NOAEL of 10 mg/kg body weight/day (2.2 mg Ni/kg b. w. /day) and a LOAEL of 30 mg/kg body weight/day (6.7 mg Ni/kg b. w. /day). The LOAEL of 6.7 mg Ni/kg bw/day based on reduced body weight and increased mortality together with a NOAEL of 2.2 mg Ni/kg bw/day is taken forward to the risk characterisation. A summary document on this topic is provided as a background document in section 7.5.1 of IUCLID and in Appendix B1of the CSR.
INHALATION: Data are read-across from Ni sulphate.Chronic lung inflammation including lung fibrosis results from long-term exposure via inhalation to a concentration of 0.25 mg nickel sulphate hexahydrate/m3 (0.056 mg Ni/m3) or A NOAEC of 0.12 mg/m³ (0.027 mg Ni/m3) was identified for these effects.
DERMAL: Testing by the dermal route has been waived as described in Section 7.5.3 of IUCLID.
Justification for classification or non-classification
Ni nitrate is classified as STOT RE 1; H372 according to the 1st ATP to the CLP. Background information supporting this classification can be found in the discussion section.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
